Trial Profile

A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients With Chemosensitive Advanced Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms PIN

Most Recent Events

22 Jul 2020 This trial has been completed in United kingdom as per European clinical trail database record ( global end of the trial 2019-02-22 )
31 May 2020 Primary endpoint (Progression-free survival) has not been met, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com